Twist Bioscience Corporation announced its fiscal third quarter 2025 financial results on August 4, 2025, reporting a net income of 33 cents per share, a significant turnaround from a loss of $1.47 a year ago. This income included a $48.85 million gain on the sale of the DNA Data Storage business, equivalent to 80 cents per share, with an adjusted loss of 47 cents per share, which still beat the analyst consensus of a 55-cent loss.
The company's sales reached $96.057 million, an increase from $81.45 million a year ago, beating the consensus of $95.47 million and falling within management's guidance range of $94 million-$97 million. Gross margin for the third quarter of fiscal 2025 increased substantially to 53.4% compared to 43.3% a year ago, reflecting improved operational efficiency and volume leverage.
Adjusted EBITDA for the quarter was $(8.0) million, a significant improvement from $(22.0) million in Q3 FY24. Twist Bioscience narrowed its fiscal year 2025 sales guidance to $374 million-$376 million and improved its adjusted EBITDA loss guidance to $(45.0) million to $(47.0) million. The company reiterated its expectation to achieve adjusted EBITDA breakeven by the end of fiscal 2026, underscoring its disciplined cost management and focused business execution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.